We are live on ! Find out more
RYTM icon

Rhythm Pharmaceuticals
RYTM

85 hedge funds and large institutions have $970M invested in Rhythm Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 38 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

750% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 4

322% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 9

100% more capital invested

Capital invested by funds: $485M → $970M (+$485M)

55% more funds holding

Funds holding: 55 → 85 (+30)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

4.32% more ownership

Funds ownership: 89.3% → 93.63% (+4.3%)

Holders
85
Holders Change
+30
Holders Change %
+54.55%
% of All Funds
1.95%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
34
Increased
38
Reduced
9
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$42.2M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$32.7M
3
BBA
Baker Bros. Advisors
New York
+$18M
4
TCM
TimesSquare Capital Management
New York
+$16.1M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$14.5M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$22.9M
2
EC
EcoR1 Capital
California
-$6.34M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$5.06M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.58M
5
Franklin Resources
Franklin Resources
California
-$2.15M
Name Holding Trade Value Shares
Change 		Change in
Stake
Alyeska Investment Group
26
Alyeska Investment Group
Illinois
$3.35M +$2.93M +107,107 New
SSA
27
Schonfeld Strategic Advisors
New York
$3M +$2.62M +96,000 New
Geode Capital Management
28
Geode Capital Management
Massachusetts
$2.84M -$780K -28,530 -24%
PC
29
PointState Capital
New York
$2.66M +$2.32M +85,000 New
LCM
30
Laurion Capital Management
New York
$2.63M +$2.3M +84,200 New
Russell Investments Group
31
Russell Investments Group
United Kingdom
$1.84M -$233K -8,523 -13%
Deutsche Bank
32
Deutsche Bank
Germany
$1.66M +$1.16M +42,547 +400%
Citadel Advisors
33
Citadel Advisors
Florida
$1.57M -$112K -4,084 -8%
Charles Schwab
34
Charles Schwab
California
$1.49M +$429K +15,695 +49%
CM
35
Crestline Management
Texas
$1.28M +$1.12M +41,047 New
AA
36
ALPS Advisors
Colorado
$1.25M +$91.8K +3,359 +9%
PP
37
PDT Partners
New York
$1.23M +$46.3K +1,693 +4%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$1.18M +$368K +13,462 +55%
D.E. Shaw & Co
39
D.E. Shaw & Co
New York
$1.18M +$1.03M +37,575 New
ClearBridge Investments
40
ClearBridge Investments
New York
$964K -$203K -7,410 -19%
Norges Bank
41
Norges Bank
Norway
$938K -$547K -20,000 -40%
Morgan Stanley
42
Morgan Stanley
New York
$927K +$352K +12,866 +77%
Swiss National Bank
43
Swiss National Bank
Switzerland
$894K +$782K +28,600 New
Millennium Management
44
Millennium Management
New York
$891K +$779K +28,502 New
PPA
45
Parametric Portfolio Associates
Washington
$867K +$192K +7,010 +34%
TCIM
46
TIAA CREF Investment Management
New York
$776K +$160K +5,854 +31%
VEA
47
Virtus ETF Advisers
New York
$762K +$666K +24,374 New
TA
48
Teachers Advisors
New York
$638K +$150K +5,491 +37%
Squarepoint
49
Squarepoint
New York
$594K +$519K +18,993 New
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$586K +$165K +6,028 +47%
1
2
3 4

RYTM Hedge Fund Activity: Q2 2018 in Review

85 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q2 2018, worth a combined $970M — up 100% from $485M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new RYTM positions and 4 closed out — a net gain of 30 holders — while 38 added to existing stakes and 9 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $42.2M. The largest seller was OrbiMed, cutting an estimated $22.9M.

  • 85 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q2 2018, up from 55 in Q1 2018.
  • Funds reported $970M of Rhythm Pharmaceuticals stock for Q2 2018, up 100% quarter-over-quarter.
  • 34 funds opened new Rhythm Pharmaceuticals positions in Q2 2018 and 4 closed out, a net change of +30 holders.
  • The largest Rhythm Pharmaceuticals buyer in Q2 2018 was RA Capital Management, an estimated $42.2M added.
  • The largest Rhythm Pharmaceuticals seller in Q2 2018 was OrbiMed, an estimated $22.9M sold.

Based on aggregated 13F filings for Q2 2018.